Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 5/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13614191 | 0.87 | LMNA (0.47) | LMNATDP1NLRP3KDM4ES1PR1 | |
| SCHEMBL6099656 | 0.85 | LMNA (0.48) | LMNATDP1NLRP3KDM4ES1PR1 | |
| SCHEMBL14968743 | 0.80 | LMNA (0.56) | LMNATDP1NLRP3KDM4ES1PR1 | |
| SCHEMBL12824692 | 0.78 | LMNA (0.43) | LMNATDP1NLRP3KDM4ES1PR1 | |
| SCHEMBL12922882 | 0.78 | LMNA (0.43) | LMNATDP1NLRP3KDM4ES1PR1 | |
| SCHEMBL388492 | 0.76 | TDP1 (0.44) | LMNATDP1NLRP3KDM4ES1PR1 | |
| SCHEMBL20381145 | 0.75 | LMNA (0.43) | LMNATDP1NLRP3KDM4ES1PR1 | |
| SCHEMBL12741150 | 0.74 | LMNA (0.43) | LMNATDP1NLRP3KDM4ES1PR1 | |
| SCHEMBL13892301 | 0.74 | LMNA (0.63) | LMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL19335086 | 0.74 | LMNA (0.40) | LMNATDP1NLRP3KDM4ES1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874739-B1 | PHARMACEUTICALLY ACTIVE DIAZEPANES | NOVARTIS AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | OBERHAUSER BERNDT | 2008-12-04 | — | — | US | disclosed |
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | OBERHAUSER BERNDT | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | VCAM1, ICAM1, CD69 | LMNA 3812/4885TDP1 2276/4885NLRP3 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.